Untreated patients with stage IIIB/IV disease with NSCLC and a performance status of @/@ were randomly assigned ( @:@ ) to receive @ mg/m ( @ ) nab-P weekly plus C ( under the curve = @ , every @ weeks ) or @ mg/m ( @ ) sb-P plus C ( under the curve = @ ) every @ weeks .